Pluristem Therapeutics (PSTI) rallies 3.6% premarket.
The company says its PLX cells "proved to be safe in an animal study assessing maternal and fetal toxicity."
When administered intramuscularly in pregnant rats, the PLX-PAD cells "did not result in any maternal or fetal toxicity."
Here's CEO Zami Aberman: "This study, together with the work performed by Dr. Brett Mitchell from Texas A&M College of Medicine,suggesting that our PLX-PAD cells are efficacious in preeclamptic animal models, is an important milestone towards our goal of initiating clinical trials for preeclampsia." (PR)